(Total Views: 491)
Posted On: 05/05/2025 10:09:03 AM
Post# of 154602
Interesting Ohm: "... As an example, breast tissue under normal conditions has a fairly low level of CCR5 expression but with breast cancer you can see a dramatic rise. What can hamper the increase in CCR5 is genetic variations unrelated to CCR5 delta 32 deletion. From everything I've seen leronlimab should be of some use in a minimum of 80% of cancer types.
Queries:
Does an initial normal low CCR5 site expression correlate with difficult to treat cancers such as tnbc?
And the converse?
Are there sites with normal high CCR5 expression prior to cancer onset? Is LL best suited as a modulator of such cancer sites? TIA.
In cancers, is an increased or decreased CCR5 count the optimal treatment result?
Queries:
Does an initial normal low CCR5 site expression correlate with difficult to treat cancers such as tnbc?
And the converse?
Are there sites with normal high CCR5 expression prior to cancer onset? Is LL best suited as a modulator of such cancer sites? TIA.
In cancers, is an increased or decreased CCR5 count the optimal treatment result?
(5)
(0)
